CLOSED
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as antidiabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitor. Track Eris Lifesciences Limited's live NSE:ERIS share price ₹1,373.40 (+1.00%), market cap ₹₹190B, P/E 29.3. MarketRipple's AI analysis covers the investment thesis, ripple-chain impact, and Healthcare sector outlook for ERIS — real-time NSE India stock intelligence.
Open
₹1,353.00
High
₹1,385.00
Low
₹1,352.50
Prev. Close
₹1,359.80
52W High
₹1,855.60
52W Low
₹1,200.00
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as antidiabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitor
Key Takeaway
Eris Lifesciences Limited is rated strong buy with a P/E of 29.3x — understand the valuation context before sizing a position.
★ Recommended
Ask AI: Is Eris Lifesciences Limited fairly valued right now?
Because a P/E of 29.3x needs to be compared against sector peers and growth expectations to be meaningful.
Continue Research
View events affecting Eris Lifesciences Limited
Because the investment case must account for macro and company-specific developments — events reveal the 'why' behind price moves.
Trace sector ripple effects
Because Healthcare moves create upstream and downstream implications that affect the entire thesis.
Intelligence Path
Growth
Govt Exposure
Policy Dependence
Execution Quality
News Sensitivity
Debt Strength
869 Cr
Revenue
142 Cr
Net Profit
0%
ROE
0%
ROCE
46.87
EPS
| ₹ in Crore | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|
| Revenue | 1,662 | 1,991 | 2,879 | 3,115 | 3,212 |
| Net Profit | 382 | 392 | 352 | 620 | 644 |
| ROE (%) | — | — | — | 0.0% | 0.0% |
| EPS (₹) | — | — | — | 46.87 | 46.87 |
| Debt/Equity | — | — | — | 60.5 | 60.5 |